INS and type 2 diabetes mellitus: Current clinical practice guidelines for T2D management recommend GLP-1RAs and dual agonists over insulin as preferred injectable options, citing their superior glycohemoglobin reduction, lower risk of hypoglycemia, and cardiorenal protective effects.